Literature DB >> 24952174

Furosemide diminishes ¹⁸F-fluoroethylcholine uptake in prostate cancer in vivo.

H Christian Rischke1, Teresa Beck, Werner Vach, Gesche Wieser, Anca L Grosu, Wolfgang Schultze-Seemann, Philipp T Meyer, Cordula A Jilg.   

Abstract

PURPOSE: (18)F-Fluoroethylcholine ((18)F-FECh) is excreted via the urinary system with high activity accumulation in the urinary bladder. Furosemide and oral hydration can be administered concomitantly to reduce urinary activity to provide better detectability of retroperitoneal and pelvic lesions. Currently it is unknown if there is any effect of furosemide on (18)F-FECh uptake in organs, tissues and tumour lesions and the extent to which image quality along the urinary tract may be improved by furosemide.
METHODS: We retrospectively analysed 217 (18)F-FECh PET/CT examinations from 213 patients with known prostate cancer (PCa), performed either with oral hydration (109) or furosemide 20 mg together with oral hydration (108). Maximum (18)F-FECh uptake in different organs, tissues, lymph nodes and osseous metastases was quantified in terms of standardized uptake value (SUV) in a volume of interest and compared between the two groups. To characterize the impact of furosemide on lesion detectability a three-point rating scale was used to assess the presence of focal activity spots in the ureters and of perivesicular artefacts.
RESULTS: Patient characteristics and distribution of tumour lesions were well balanced between the two groups. Overall, SUVmax values from normal organs were increased after furosemide compared to the values in patients scanned without furosemide. Significant changes were observed in the salivary glands, liver, spleen, pancreas, kidneys, gluteus muscle and perirenal fat. SUVmax values were significantly decreased after furosemide in lymph node metastases (SUVmax 4.81 ± 2.68 vs. 6.48 ± 4.22, p = 0.0006), but not in osseous metastases. Evaluation of image quality along the urinary tract revealed significantly better depiction of the perivesicular space and significantly less focal tracer accumulation in the ureters in patients receiving furosemide, but the number of detected lymph nodes was not significantly different.
CONCLUSION: Furosemide administration reduced choline uptake in tumour lesions, especially significant in pelvic lymph node metastases. Although furosemide administration improved image quality, optimal image quality may also be obtained by adequate hydration without the risk of diminishing choline uptake in PCa lesions. Therefore a controlled hydration protocol seems more appropriate than administration of furosemide.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24952174     DOI: 10.1007/s00259-014-2829-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  43 in total

Review 1.  Choline transport for phospholipid synthesis.

Authors:  Vera Michel; Zongfei Yuan; Shobha Ramsubir; Marica Bakovic
Journal:  Exp Biol Med (Maywood)       Date:  2006-05

2.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

Authors:  Mohsen Beheshti; Larisa Imamovic; Gabriele Broinger; Reza Vali; Peter Waldenberger; Franz Stoiber; Michael Nader; Bernhard Gruy; Guenter Janetschek; Werner Langsteger
Journal:  Radiology       Date:  2010-03       Impact factor: 11.105

3.  Furosemide, a blocker of Na+/K+/2Cl- cotransporter, diminishes proliferation of poorly differentiated human gastric cancer cells by affecting G0/G1 state.

Authors:  Atsushi Shiozaki; Hiroaki Miyazaki; Naomi Niisato; Takashi Nakahari; Yoshinobu Iwasaki; Hirosumi Itoi; Yuji Ueda; Hisakazu Yamagishi; Yoshinori Marunaka
Journal:  J Physiol Sci       Date:  2006-10-21       Impact factor: 2.781

Review 4.  Long-term adaptation of renal ion transporters to chronic diuretic treatment.

Authors:  Gheun-Ho Kim
Journal:  Am J Nephrol       Date:  2004-11-23       Impact factor: 3.754

5.  Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging.

Authors:  Toshihiko Hara; Noboru Kosaka; Hiroichi Kishi
Journal:  J Nucl Med       Date:  2002-02       Impact factor: 10.057

6.  Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

Authors:  Martin Heinisch; Albert Dirisamer; Wolfgang Loidl; Franz Stoiber; Bernhard Gruy; Silke Haim; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

7.  Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies.

Authors:  Ehab M Kamel; Patrice Jichlinski; John O Prior; Jean-Yves Meuwly; Jean-Francois Delaloye; Laurent Vaucher; Jerome Malterre; Sandra Castaldo; Hans-Juerg Leisinger; Angelika Bischof Delaloye
Journal:  J Nucl Med       Date:  2006-11       Impact factor: 10.057

Review 8.  Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors:  Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

9.  Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer.

Authors:  C A Jilg; H C Rischke; S N Reske; K Henne; A-L Grosu; W Weber; V Drendel; M Schwardt; A Jandausch; W Schultze-Seemann
Journal:  J Urol       Date:  2012-10-18       Impact factor: 7.450

10.  Improved automated synthesis of [18F]fluoroethylcholine as a radiotracer for cancer imaging.

Authors:  M Piel; A Bauman; R P Baum; S Höhnemann; I Klette; R Wortmann; F Rösch
Journal:  Bioorg Med Chem       Date:  2007-02-22       Impact factor: 3.641

View more
  2 in total

1.  PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients.

Authors:  Jingjing Zhang; Gang Niu; Xinrong Fan; Lixin Lang; Guozhu Hou; Libo Chen; Huanwen Wu; Zhaohui Zhu; Fang Li; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2017-11-09       Impact factor: 10.057

2.  MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.

Authors:  Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.